Achalasia Medical Services in China

Achalasia is a rare primary esophageal motility disorder characterized by the failure of the lower esophageal sphincter (LES) to relax adequately during swallowing, coupled with absent or ineffective peristalsis in the distal two-thirds of the esophageal body. This functional obstruction leads to progressive dysphagia (initially for solids, later for liquids), regurgitation of undigested food, retrosternal discomfort, and weight loss. Pathophysiologically, achalasia results from degeneration and loss of inhibitory ganglion cells—particularly nitric oxide synthase (NOS)- and vasoactive intestinal peptide (VIP)-expressing neurons—in the myenteric plexus of the esophagus. The exact etiology remains unclear but is thought to involve autoimmune, viral (e.g., herpes simplex virus-1, measles), and genetic components, with growing evidence of chronic inflammatory infiltration and neuronal apoptosis. Epidemiologically, achalasia affects approximately 1–1.6 per 100,000 individuals annually worldwide, with a prevalence of 10–12 per 100,000. It occurs equally across sexes and most commonly presents between ages 25 and 60, though pediatric and geriatric cases are documented. No definitive environmental or lifestyle risk factors have been established; however, familial clustering and associations with certain HLA haplotypes (e.g., HLA-DQB1*05:01) suggest a genetic predisposition. Autoimmune comorbidities—including type 1 diabetes, Sjögren’s syndrome, and thyroid disease—are observed more frequently than in the general population. Quality of life is significantly impaired: patients report chronic fatigue, social withdrawal due to meal-related anxiety and embarrassment, sleep disruption from nocturnal regurgitation and aspiration, and heightened risk of aspiration pneumonia and esophageal squamous cell carcinoma (with lifetime risk estimated at 2–7%). Untreated, symptoms worsen progressively, leading to esophageal dilation (megaesophagus), stasis, and structural remodeling. Early diagnosis—via high-resolution manometry (HRM), barium esophagram, and upper endoscopy—is critical to guide appropriate intervention and prevent irreversible esophageal damage.

Achalasia is a primary esophageal motility disorder characterized by impaired relaxation of the lower esophageal sphincter (LES) and absent or ineffective peristalsis in the distal esophagus. The fundamental pathophysiology involves progressive degeneration and loss of inhibitory neurons—particularly nitric oxide synthase (NOS)- and vasoactive intestinal peptide (VIP)-expressing neurons—in the myenteric plexus of the esophageal wall. This neuronal loss leads to unopposed cholinergic excitatory activity, resulting in LES hypertonicity and failure of receptive relaxation during swallowing. While the precise etiology remains incompletely understood, current evidence supports a multifactorial origin involving autoimmune, neurodegenerative, infectious, and genetic mechanisms.

Common causes are not attributable to structural obstruction (e.g., malignancy or strictures), distinguishing achalasia from secondary or pseudoachalasia. Rather, it is classified as a primary idiopathic disorder; however, emerging research implicates chronic immune-mediated injury to the esophageal myenteric plexus. Autoantibodies targeting neuronal antigens—including anti-ganglion antibodies and antibodies against nuclear envelope proteins (e.g., anti-NOVA, anti-Hu)—have been detected in subsets of patients, suggesting an underlying autoimmune process. Additionally, viral triggers—particularly herpesviruses (e.g., HSV-1, EBV) and measles virus—have been proposed due to histopathological evidence of inflammatory infiltrates (lymphocytic ganglionitis) in early-stage disease and molecular mimicry between viral epitopes and neuronal proteins.

Triggers are poorly defined but may include acute viral gastroenteritis or systemic inflammatory events that precipitate or unmask subclinical neuronal dysfunction. Psychological stress and dietary factors (e.g., chronic consumption of very hot beverages or irritants) are not established triggers, though symptom exacerbation can occur with rapid eating, carbonated beverages, or lying supine postprandially.

Established risk factors include age (peak incidence between 25–60 years, rare in children and elderly >80), sex (slight male predominance in some cohorts), and coexisting autoimmune conditions—such as type 1 diabetes mellitus, Sjögren syndrome, lupus erythematosus, and thyroid autoimmunity—which occur at higher prevalence than in the general population. A history of prior gastric surgery (e.g., vagotomy) is not a risk factor for classic achalasia but may cause similar functional impairment via iatrogenic denervation.

Genetic factors play a modest role. Achalasia is predominantly sporadic, but familial clustering occurs in ~1–3% of cases. Genome-wide association studies (GWAS) have identified susceptibility loci within the HLA class II region (notably HLA-DQB1*05:01 and HLA-DRB1*11:01), reinforcing the autoimmune hypothesis. Polymorphisms in genes involved in neuronal development and immune regulation—including IL23R, LPP, and C6orf10—have also been associated. Rare monogenic forms linked to ALDH1A2 mutations (affecting retinoic acid metabolism critical for enteric nervous system development) and familial dysautonomia (IKBKAP mutations) demonstrate overlapping esophageal motor dysfunction, though these represent distinct syndromes rather than typical achalasia.

Environmental factors remain speculative but epidemiologically plausible. Geographic variation—higher prevalence in certain regions (e.g., parts of South America and Asia) and urban settings—suggests potential roles for endemic infections or environmental toxins. Chronic exposure to pesticides or heavy metals has not been validated in human studies, though experimental models show enteric neuronal toxicity. Socioeconomic status shows no consistent association. Notably, smoking and alcohol use are not causally linked to achalasia development, though smoking may worsen symptom severity and impair treatment response. Importantly, achalasia is not associated with GERD, obesity, or hiatal hernia—conditions commonly conflated in clinical practice. Early diagnosis hinges on recognizing hallmark symptoms (dysphagia to solids and liquids, regurgitation, chest pain, weight loss) and confirming manometric criteria (Chicago Classification v4.0): integrated relaxation pressure (IRP) >15 mmHg, 100% failed peristalsis, and absence of normal pan-esophageal pressurization. Understanding this complex interplay of neuroimmune degeneration, genetic susceptibility, and potential environmental cofactors is essential for accurate diagnosis, prognostication, and future targeted therapies.

Achalasia is a primary esophageal motility disorder characterized by impaired relaxation of the lower esophageal sphincter (LES) and absent or ineffective peristalsis in the distal esophagus. It results from progressive degeneration of inhibitory ganglion cells—particularly nitric oxide synthase (NOS)- and vasoactive intestinal peptide (VIP)-expressing neurons—in the myenteric plexus of the esophageal wall. This neurodegenerative process leads to functional obstruction at the gastroesophageal junction, with consequent esophageal dilation, stasis, and symptomatology primarily related to dysphagia and regurgitation.

Early symptoms of achalasia are often subtle and insidious, frequently misattributed to gastroesophageal reflux disease (GERD) or functional dyspepsia. Patients may report intermittent, non-progressive dysphagia—initially more pronounced for solids than liquids—occurring over months to years. Early-stage dysphagia is typically postprandial, relieved by drinking water or changing posture (e.g., upright positioning or gentle rocking). Some patients describe a sensation of food 'sticking' in the mid- or lower sternum, without associated pain. Mild, non-acidic regurgitation of undigested food—especially when supine or bending forward—may occur but is often dismissed as occasional indigestion. Weight loss is uncommon early on, though subtle reductions in dietary intake due to anticipatory avoidance of solid foods may begin. Importantly, heartburn is reported in up to 40% of early cases; however, this reflects esophageal stasis-induced mucosal irritation rather than true acid reflux, and classic GERD features (e.g., response to proton pump inhibitors, nocturnal burning, water brash) are typically absent.

Typical (established) symptoms reflect progressive neuromuscular dysfunction. Dysphagia becomes persistent, affecting both solids and liquids equally in advanced stages—a hallmark distinguishing achalasia from mechanical strictures or malignancy. Regurgitation increases in frequency and volume, often occurring hours after meals or nocturnally, leading to pulmonary aspiration, chronic cough, or recurrent bronchitis. Patients may develop a characteristic 'gurgling' or 'splashing' sound on auscultation over the precordium (‘cardiac splash’), reflecting retained fluid and air in a dilated esophagus. Odynophagia is rare unless complicated by esophagitis or candidiasis. Chest pain—often retrosternal, pressure-like, and non-exertional—occurs in ~30–40% of patients and may mimic angina; it is thought to arise from esophageal spasm or distension-induced visceral afferent stimulation. Significant unintentional weight loss (>5% body weight) is common in longstanding disease due to caloric restriction and fear of eating.

Accompanying symptoms include halitosis (from bacterial overgrowth in stagnant esophageal contents), hypersalivation (sialorrhea), and nocturnal choking or coughing spells secondary to aspiration. Chronic microaspiration may lead to hoarseness, laryngopharyngeal reflux symptoms (e.g., globus sensation, throat clearing), and dental erosion. Some patients report early satiety or epigastric fullness, particularly if the esophagus is markedly dilated and compresses adjacent structures. Anxiety and depression are prevalent comorbidities, linked to symptom chronicity, diagnostic delays (average time to diagnosis: 4–5 years), and reduced quality of life.

Complications arise from prolonged stasis and elevated intraluminal pressure. Esophagitis (often Candida-associated or reflux-induced) and ulceration may develop, increasing bleeding risk. Megaesophagus—defined as esophageal diameter >6 cm on imaging—predisposes to spontaneous rupture (Boerhaave syndrome), albeit rare. Chronic aspiration pneumonia, bronchiectasis, and interstitial lung disease can result from recurrent microaspiration. Squamous cell carcinoma of the esophagus occurs at a 15–to-30-fold increased incidence compared with the general population, with cumulative risk rising after 15–20 years of untreated disease; surveillance endoscopy is recommended in longstanding cases. Nutritional deficiencies—including iron-deficiency anemia, vitamin B12 deficiency, and hypoalbuminemia—may emerge secondary to malabsorption and chronic inflammation.

Diagnosis relies on a multimodal approach. High-resolution esophageal manometry (HRM) is the gold standard: it demonstrates ≥100% failed peristalsis in the distal esophagus, incomplete LES relaxation (integrated relaxation pressure >15 mmHg), and absence of normal pan-esophageal pressurization. The Chicago Classification v4.0 defines three subtypes (I, II, III) based on pressurization patterns, guiding therapeutic decisions. Barium esophagography reveals characteristic findings: tapering of the distal esophagus ('bird’s beak' appearance), esophageal dilation, delayed emptying, and absence of peristaltic waves. Endoscopy is mandatory to exclude pseudoachalasia (e.g., gastric cardia or distal esophageal malignancy), assess mucosal integrity, obtain biopsies if suspicious, and rule out infectious esophagitis. Endoscopic ultrasound may be used if malignancy is suspected. pH-impedance testing typically shows low acid exposure time (<4%), helping differentiate from GERD; however, weakly acidic or non-acid reflux may still occur secondary to stasis.

Differential diagnosis is critical to avoid missing treatable mimics. Pseudoachalasia—most commonly caused by infiltrative malignancies (e.g., adenocarcinoma of gastric cardia, lymphoma, metastatic disease)—presents identically but affects older patients, progresses rapidly, and often shows irregular narrowing or mass lesions on imaging/endoscopy. Diffuse esophageal spasm and nutcracker esophagus feature preserved LES relaxation and intact peristalsis on manometry. Scleroderma-related esophageal dysmotility exhibits hypotensive LES pressure and fragmented peristalsis, not absent peristalsis. Chagas disease (endemic in Latin America) causes identical pathology via destruction of myenteric plexus neurons by Trypanosoma cruzi; serology and epidemiologic history distinguish it. Other considerations include eosinophilic esophagitis (with prominent rings, furrows, and eosinophil-predominant histology), radiation-induced stricture, and post-surgical complications (e.g., after fundoplication). Functional dysphagia requires exclusion of organic disease and is diagnosed only after thorough structural and motility evaluation yields normal findings.

Achalasia is a primary esophageal motility disorder characterized by absent peristalsis in the distal esophagus and impaired relaxation of the lower esophageal sphincter (LES) during swallowing. This results in progressive dysphagia for solids and liquids, regurgitation of undigested food, chest pain, and weight loss. Diagnosis relies on high-resolution manometry (HRM), which confirms the classic findings of pan-esophageal pressurization, absence of peristalsis, and incomplete LES relaxation (integrated relaxation pressure >15 mmHg). Barium esophagram typically shows a dilated, aperistaltic esophagus with a 'bird’s beak' tapering at the gastroesophageal junction, while upper endoscopy excludes mechanical obstruction or malignancy.

Conservative management plays a limited but pragmatic role—primarily as a bridge to definitive therapy or for patients who are poor surgical candidates. Lifestyle modifications include eating slowly, chewing thoroughly, drinking ample fluids with meals, avoiding late-night eating, and sleeping with the head of the bed elevated ≥30 degrees to reduce nocturnal regurgitation and aspiration risk. Patients should avoid foods that exacerbate symptoms (e.g., tough meats, raw vegetables, carbonated beverages) and refrain from lying supine within two hours of eating. While these measures do not alter disease progression, they improve symptom control and nutritional status, particularly in elderly or frail individuals.

Pharmacologic therapy has modest efficacy and is rarely used as first-line treatment. Nitrates (e.g., isosorbide dinitrate 2.5–5 mg sublingually 10–15 minutes before meals) and calcium channel blockers (e.g., nifedipine 10–20 mg orally before meals) induce transient LES relaxation via smooth muscle vasodilation. However, their effects are short-lived (30–60 minutes), tolerance develops rapidly, and systemic side effects—including headache, hypotension, and peripheral edema—limit long-term adherence. Botulinum toxin A (Botox®) injection into the LES under endoscopic guidance provides more sustained relief (median duration 6–12 months) by inhibiting acetylcholine release from myenteric plexus neurons. Though minimally invasive and well-tolerated, Botox is reserved for high-risk patients (e.g., severe cardiopulmonary comorbidities, advanced age >80 years) due to its temporary effect and potential to complicate subsequent surgical myotomy via fibrosis. Repeat injections yield diminishing returns and are not recommended beyond two sessions.

Definitive therapy centers on reducing LES resistance. Pneumatic dilation (PD) remains a cornerstone non-surgical intervention. Under fluoroscopic or endoscopic guidance, a calibrated balloon (typically 30–40 mm) is inflated across the LES for 60–90 seconds, inducing controlled tearing of circular muscle fibers. Success rates range from 70% to 90% at one year, though recurrence occurs in ~30% of patients by five years. Major risks include perforation (1–3%), which mandates immediate surgical consultation, and gastroesophageal reflux disease (GERD) in up to 30% of cases—necessitating lifelong proton pump inhibitor (PPI) therapy and surveillance for Barrett’s esophagus. PD is contraindicated in patients with prior failed myotomy or suspected esophageal diverticula.

Surgical treatment offers durable symptom control. Laparoscopic Heller myotomy (LHM) with partial fundoplication (typically Dor or Toupet) is the gold standard for fit patients. The procedure involves lengthwise division of the LES and distal esophageal circular muscle (≥2 cm proximal, ≥2 cm distal to the GEJ), followed by an antireflux wrap to mitigate postoperative GERD. Meta-analyses report >90% long-term success, with symptom resolution sustained in >85% at 10 years. Robotic-assisted LHM is increasingly adopted in tertiary centers, offering enhanced dexterity and visualization—particularly beneficial in obese or anatomically complex patients. Peroral endoscopic myotomy (POEM) represents a major advancement: an incisionless, transoral endoscopic technique creating a submucosal tunnel from 10–12 cm proximal to the GEJ, followed by circumferential myotomy of the LES and distal esophagus. POEM achieves comparable efficacy to LHM (>90% symptom improvement at 2 years), with shorter hospital stays (1–2 days), faster return to normal activity (<1 week), and no external incisions. However, it carries a higher incidence of post-procedure GERD (up to 45%), requiring routine pre- and postoperative pH-impedance testing and vigilant PPI use. Both LHM and POEM require expertise; outcomes correlate strongly with operator volume and institutional experience.

China offers distinct advantages in achalasia management. First, China hosts some of the world’s highest-volume centers for POEM—pioneered by Dr. Pinghong Zhou in Shanghai—and maintains rigorous national training standards through the Chinese Society of Gastrointestinal Endoscopy. Second, integrated multidisciplinary care is standardized: HRM, timed barium swallow, endoscopy, and pH-impedance testing are routinely available in tier-3 hospitals, enabling precise phenotyping (e.g., Chicago Classification subtypes I–III) to guide personalized therapy selection. Third, cost-effectiveness is notable: POEM and LHM are widely covered under China’s Basic Medical Insurance, with out-of-pocket expenses significantly lower than in Western countries. Fourth, rapid innovation adoption is facilitated by streamlined regulatory pathways—the National Medical Products Administration (NMPA) approved next-generation endoscopic platforms (e.g., dual-channel therapeutic endoscopes with real-time elastography) within 12 months of CE/US FDA clearance. Finally, longitudinal follow-up is robust: national registries track >50,000 achalasia patients, supporting evidence-based refinements in postoperative GERD monitoring and nutritional rehabilitation protocols.

Post-treatment recovery emphasizes structured re-feeding and vigilant surveillance. After PD or surgery, patients begin clear liquids on post-procedure day one, advancing to soft, non-fibrous foods over 7–10 days. Solid foods are reintroduced gradually over 3–4 weeks; meat, bread crusts, and raw produce are avoided for ≥6 weeks. All patients undergo repeat HRM and/or timed barium swallow at 3 months to assess functional improvement. GERD screening via ambulatory pH-impedance is mandatory at 6 months and annually thereafter. Nutritional counseling is integral: registered dietitians assess caloric intake, screen for micronutrient deficiencies (especially iron, vitamin B12, and fat-soluble vitamins), and recommend oral supplements if needed. Patients are advised to maintain upright posture for ≥30 minutes after meals, avoid tight waistbands, and report alarm symptoms—new-onset odynophagia, hematemesis, or unexplained weight loss—promptly, as these may indicate complications or alternative diagnoses. Long-term prognosis is excellent with appropriate intervention: >95% of treated patients achieve meaningful symptom relief and preserved quality of life, underscoring the importance of timely referral to specialized digestive disease centers.